Company intelligence / Profile preview

CIMOF

Basel, Switzerlandcimof.fr ↗

Ownership: Private
Employees: ~35
Development stage: Commercial

Overview

Cimeio’s SCIP platform has demonstrated preclinical proof-of-concept for shielding hematopoietic stem cells from depletion by various immunotherapies. The technology enables selective targeting and elimination of diseased cells while protecting healthy transplanted cells, potentially transforming outcomes in HSC transplant and adoptive cell therapies. Clinical candidates were expected to be ready by late 2022/early 2023; no clinical results have been published yet.

Therapeutic areas: ImmunologyOncologyRare Diseases
Modalities: Gene therapyCell therapyMonoclonal antibodyAntibody-drug conjugate (ADC)T-cell engagerCAR-T cell therapy
Industry: Biotech

Partnerships

Kyowa Kirin—collaboration on innovative immunotherapy development using shielded cell technology, with up to $300 million in deal value announced December 2024Prime Medicine—collaboration announced May 2023 combines Prime Editing with SCIP platform for improved safety/effectiveness in genetic blood disorders including AML/MDS

Beyond the preview

Go deeper on CIMOF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIMOF.

Explore the full profile